Diabetes - Slitt

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/111

encourage image

There's no tags or description

Looks like no tags are added yet.

112 Terms

1
New cards

MOA of obesity to insulin resistance

Obesity increases the number of adipocytes

The increase in adipocytes leads to: increased mass, chronic inflammation, hypoxia, oxidative stress, and ER stress

These factors lead to an increase in Adipocytokines TNF-a and IL-6 which lead to inflammation

These factors also decrease adiponectin which normally increases insulin sensitivity

2
New cards

Pancreas and BG levels - low BG

Pancreas senses low BG

Pancreas releases glucagon from alpha cells

In response to glucagon the liver turns glycogen into glucose

Glucose enters the blood to achieve normal BG

3
New cards

Pancreas and BG levels - high BG

Pancreas sense high BG

Pancreas releases insulin from beta cells

In response to insulin fat cells take glucose up from the blood

Glucose leaves the blood achieving normal BG

4
New cards

MOA of glucagon

Glucagon is released

It binds to glucagon receptor and activates AC

AC activates AMP making cAMP

Activates PKA

Increases Fructose 6-P from PEP

Increases glucose production

5
New cards

Insulin function

Insulin is necessary for metabolic homeostasis. Too much or too little systemic insulin is not healthy for the body from a metabolic standpoint.

6
New cards

Too much insulin

Will lead to promoted fat storage and eventually cause insulin resistance

7
New cards

Too little insulin

Results in hyperglycemia which can be very harmful to the body (damage nerves, blood vessels, tissues and organs)

8
New cards

Generally how does insulin lower BG

Stimulating peripheral glucose uptake especially by skeletal muscle and fat

Inhibiting hepatic glucose production

Insulin inhibits lipolysis in adipocytes, inhibits proteolysis and enhances protein synthesis. In other words it inhibits the liberation of fat cells as free fatty acids.

9
New cards

Insulin processing

Proinsulin is the prohormone precursor to insulin made in the beta cells of the islets of Langerhans, a specialized region of the pancreas. In humans proinsulin is encoded by the INS gene

10
New cards

MOA of insulin

When insulin binds to its receptor the Glut-4 receptor gets activated

Translocation of the glut-4 to the cell membrane occurs

The transporter is then able to take glucose from circulation and bring it into the cell

Once in the cell glucose can be used for cellular processes or converted into glycogen if it is not needed for immediate use

Glucose can also be converted into pyruvate which then gets converted into fatty acids which then gets converted to TGs and stored as fat.

11
New cards

What happens to insulin in T1D

No insulin is being produced. It can not bind to insulin receptor and stimulate glucose uptake or conversion of glucose to fatty acids

12
New cards

What happens to insulin in T2D

The skeletal muscle and adipose tissue become resistant to insulin. There is a decreased amount of signaling capacity for the IR. Glut-4 levels are decreased

13
New cards

Two pathways of insulin receptor

metabolic signals and growth signals

14
New cards

MOA of metabolic signals of insulin receptor

Insulin binds to its receptor activating IRS

IRS phosphorylates AKT

AKT triggers many things:

  • glucose uptake

  • Protein synthesis

  • Glycogen synthesis

  • Inhibits PEPC-K and IGF


15
New cards

MOA of growth signals of insulin receptor

Insulin binds to its receptor activating IRS and Shc

Shc drives ERK pathway

IRS activates p38 and JNK pathways

Associated with cell proliferation - important for cancer

16
New cards

Effect of glucagon in PEPC-K

Glucagon upregulates PEPC-K increasing glucose production in the liver

17
New cards

Rate limiting step of glucose synthesis

Oxaloacetic acid getting converted to PEP (phosphoenolpyruvate) via PEPC-K

18
New cards

Insulin effect on PEPC-K

Insulin downregulates PEPC-K decreasing glucose production in the liver

19
New cards

How does glucose production in the liver impact insulin resistance

If someone is insulin resistant, after they eat you do not want the liver to be making extra glucose when it doesn’t need to. This contributes to hyperglycemia.

20
New cards

MOA of injected insulin preparation

To mimic and stimulate insulin receptor signaling

21
New cards

Normal insulin structure

Monomer

Consists of alpha and beta chain

These chains can be modified to adjust duration of action

22
New cards

What form does insulin need to be in to interact with its receptor

Monomeric.

It can exist in dimeric and hexameric forms.

Short acting insulins tend to stay a monomer, while longer acting may be in hexamer or dimer forms

23
New cards

Rapid acting insulin types

Lispro

Aspart

Glulisine

Inhaled (Afrezza)

24
New cards

Short acting insulin types

Regular

25
New cards

Intermediate acting insulin types

NPH

26
New cards

Long acting insulin types

Glargine

Detemir

Degludec

27
New cards

Onset of rapid acting insulins

~15 minutes

28
New cards

Peak action of rapid acting insulins

~30 minutes - 1 hour

29
New cards

Duration of rapid acting insulins

3-4 hours

30
New cards

Onset of short acting insulin

~ 30 minutes

31
New cards

Peak action of short acting insulins

~2-3 hours

32
New cards

Duration of short acting insulins

~3-6 hours

33
New cards

Onset of intermediate acting insulins

~2-4 hours

34
New cards

Peak action of intermediate acting insulins

~6-10 hours

35
New cards

Duration of intermediate acting insulins

~10-16 hours

36
New cards

Onset of long acting insulins

30 minutes - 1.5 hours

37
New cards

Peak action of long acting insulins

no definitive peaks or ~8 hours for some

38
New cards

Duration of long acting insulins

~24 hours

39
New cards

Insulin lispro

First monomeric insulin analog

Recombinant human insulin

Equipotent to human insulin on a molar basis

Effect is more rapid and shorter in duration

40
New cards

What changes were made in insulin lispro

2 amino acids (Lys and Pro) near carboxyl terminal of the B chain have been reversed to make the insulin more monomeric

41
New cards

Lispro ADME

55-77% Bioavailability

Peak concentration in 30-90 minutes

Onset 5-15 minutes

Vdistribution is the same as insulin

SubQ dose has shorter t1/2

42
New cards

Insulin Aspart (Novolog)

Recombinant human insulin made in yeast

More rapid onset and shorter duration

Reduces monomer: monomer interaction between Pro-B-28 and Gly-B-23

43
New cards

What changes were made in insulin aspart

Proline amino acid was removed, aspartic acid was added at B-28 position

44
New cards

What changes were made in insulin Glulisine (Apidra

At B-3 position asparagine was replaced with lysine

At B-29 position lysine was replace with glutamic acid

45
New cards

Insulin Glulisine

Is a rapid acting insulin analogue that differs from human insulin in that the amino acids at B3 and B29 were replaced

It is similar to other rapid acting insulins

Given IV it has the same effect as regular insulin

Give SubQ is has more rapid onset but shorter duration that insulin

46
New cards

Novolin and Humulin R

Short acting

Effect appears within 30 minutes and peaks 2-3 hours after SubQ injection, generally lasting 5-8 hours

Formation of hexamers and dimers are important for its absorption

47
New cards

Difference in dissolution between IV and SubQ

IV: insulin is administered as hexamers and immediately dissolves to monomers

SubQ: Insulin is administered as hexamers and has to dissolve to dimers then monomers. Slower process

48
New cards

Novolin and Humulin N

Intermediate Acting

Not tested on, less used

49
New cards

Long acting insulins

Reaches the blood stream in 1-3 hours, does not peak and lasts for up to 24 hours

Levemir/Detemir

50
New cards

Ultra long acting

Reaches the long stream in 4-6 hours, does not peak, and lasts 24 hours or longer

Glargine/Lantus/Tujeo

Degludec/Tresiba

51
New cards

Insulin detemir

Long acting

Duration of action is 5.7-23.5 hours

Modification increases aggregation in sc tissue, thereby slows release from the tissues into systemic circulation

Reversible albumin binding

52
New cards

What changes were made in insulin determir

Terminal threonine is dropped from the B-30 position and myristic acid ist attached to there terminal B-29 lysine

53
New cards

Insulin Glargine

Duration of action is 24 hours

Soluble in acidic solution but precipitates in more neutral body pH after SubQ injection. The precipitate is then slowly released.

Has active M1 and M2 metabolites which have similar affinity for the insulin receptor

54
New cards

What changes were made in insulin glargine

2 arginine molecule are attached to the beta-chain carboxyl terminal and substitution of a glycine for asparagine at the A-21 position

55
New cards

Toujeo

An insulin glargine

Ultra long acting

Designed to slowly release small amounts of insulin for the gull 24 hours

Package in U-300 (lantus is U-100), lasts longer in the body

56
New cards

Insulin Degludec

Duration >42 hours

Formulated with hexadecanedioic acid, which allows the insulin to form soluble multi-hexamers once injected and results in a slower release of insulin into the bloodstream

57
New cards

Immunopathology of insulin preps

Insulin allergy

Allergy to non-insulin protein contaminants

Immune insulin resistance

58
New cards

Glucose infusion rate

Is a measure of how quickly the patient receives carbs, indirect measure of the insulin activity

59
New cards

Kinds of non-insulin anti diabetic agents

Biguanides

Thiazolidinediones

Incretin based therapies

SGLT2 inhibitors

Insulin Secretagogues

60
New cards

Metformin (Glucophage)

Widely used in treatment of T2D

T1/2 of 1.5-3 hours

Renally cleared, not metabolized or excreted by kidneys as active compound

Consider patient renal function

61
New cards

Functions of AMPK

AMP-activated protein kinase (AMPK) normally phosphorylates other proteins and modifies signaling/function. Metformin is an AMPK activator, it increases p-AMPK

62
New cards

Major effects of metformin

Decrease glucose production in the liver

Decrease glucose output via activation of the enzyme AMP-activates protein kinase (AMPK)

63
New cards

Minor Effects of metformin

Impairment of renal gluconeogenesis

Slowing of glucose absorption from the GI tract

Increased glucose to lactate conversion in enterocytes

Direct stimulation of glycolysis in tissues

Increased glucose removal from the blood

64
New cards

Adverse Effects of Metformin

Diarrhea - it increases intestinal motility, malabsorption

Vitamin B-12 deficiency

Lactic Acidosis

65
New cards

Metformin MOA via AMPK-P

Decreases conversion of lactate to pyruvate

Decreases production of lactate from glycerol

Down regulates PEPC-K

Decreases OAA formation

Enhances Glut4 expression and uptake of glucose into the muscle

66
New cards

Metformin action in the hepatocytes

AMPK phosphorylates things

Decreases PEPC-K mRNA and protein expression

Decreases G6P mRNA and protein expression (important for glucose production in liver)

Decreasing lactate to pyruvate conversion → decreasing OAA to PEP

Decreases glucose output from liver

67
New cards

What are incretins

Incretins are hormones found in the gut. They are secreted after nutrient intake and stimulate insulin secretion together with hyperglycemia. Stimulate release of insulin during a meal even before glucose levels rise.

68
New cards

GLP-1

Glucagon life protein is produced in L-cells of intestine.

Short ½ life of 1.5-5 minutes

69
New cards

GIP

Gastrin Inhibitory peptide, produced by K-cells of duodenum and ileum.

Short ½ life of 5-7 minutes

70
New cards

Main actions of Incretins

GLP-1 stimulates insulin release from the pancreas

GLP-1 inhibits glucagon release from the pancreas

71
New cards

DPP4

Inactivates GLP-1 by breaking it apart

72
New cards

DPP4 inhibitors

Block DPP4

Inhibit breakdown of GLP-1

Oral administration

Non selective and non-specific effects

Less side effects compared to GLP-1 agonists

73
New cards

Multiple actions of Incretins

Potentiation’s of glucose mediated insulin secretion

Suppression of postprandial glucagon release

Slowed Gastric emptying

Decreased Appetite

Possible increase in beta cell mass - anti-apoptotic role in beta cells

74
New cards

Forms of incretins

Analogs that mimic GLP-1

DPP4 inhibitors that inhibit GLP-1 breakdown

75
New cards

What causes the release of incretins

Glucose

Amino acids

Lipids

76
New cards

Where are incretin receptors located

Alpha and beta cells of the pancreas

77
New cards

Incretin Analogs

These drugs are analogues of GLP-1 and are designed to act like GLP-1

Modification to GLP-1 molecules alter half life and duration of action

78
New cards

Neurotransmission of the gut

Can also stimulate islet cells and release pancreatic secretions

79
New cards

GLP-1 Agonists vs DPP4 Inhibitors

More A1C reduction with GLP-1 Agonists

More effect on post prandial glucose with agonists

Delayed gastric emptying with glucose

Agonists effect satiety and weight loss

Agonists can cause dose related nausea and have potential CNS side effects


These effects are not seen with DPP4 inhibitors because they only work on an endogenous/normal amount of hormone

<p>More A1C reduction with GLP-1 Agonists </p><p>More effect on post prandial glucose with agonists</p><p>Delayed gastric emptying with glucose </p><p>Agonists effect satiety and weight loss </p><p>Agonists can cause dose related nausea and have potential CNS side effects </p><p></p><p>These effects are not seen with DPP4 inhibitors because they only work on an endogenous/normal amount of hormone </p>
80
New cards

Exenatide (Byetta)

Synthetic analog of glucagon like polypeptide 1

Administered 2x/day

39 amino acid peptide

Peptidase resistant

T1/2 of 2.4 hours

1st incretin therapy, often used in conjunction with metformin or sulfonylureas

81
New cards

Bydureon

New formulation of Exenatide

Long acting release

Following a single dose exenatide is released over approximately 10 weeks from microspheres

82
New cards

Liraglutaide (Victoza)

Synthetic analog of GLP-1

Administered once a day

97% of amino acid homology to the endogenous GLP-1

Administered SQ as an isotonic solution

T1/2 is 13 hours

Has 16-C fatty acid moiety attached to it. This binds albumin and prolongs half life.

83
New cards

Dulaglutide (Trulicity)

Once a week

GLP-1 analogue

Has 3 substitutions and then fusion of the GLP-1 to a synthetic Ig4 Fc fragment

Very resistant to DPP4 degradation

T1/2 is 3.75-5 days

84
New cards

Lixisenatid (Adlyxin)

GLP-1 agonist

Administered once daily

C-terminal modification of the addition of 6 lysine residues and deletion of a proline

4x higher binding affinity for the GLP-1 receptor compared to native GLP-1

Considered short acting

T1/2 is 3 hours but its high affinity allows for daily dosing

85
New cards

Semaglutide (Ozempic)

Once weekly dosing

C-18 glutamic acid ADO linker which has affinity for human serum albumin which allows for long t1/2 of 7 days

86
New cards

Examples of DPP4 inhibitors

Gliptins

87
New cards

MOA of Gliptins

Work by blocking the action of DPP4 an enzyme that destroys incretins

88
New cards

AEs of incretins

nausea, diarrhea, and stomach pain

Flu-like symptoms HA, runny nose, sore throat

Skin reaction - red/purple rash

Joint pain

89
New cards

Which gliptins are renally cleared

Sitagliptin

Saxagliptin

Vildagliptin

Alogliptin


Need renal dose adjustments

90
New cards

Which gliptin is hepatically cleared

Linagliptin - does not need dose adjustment

91
New cards

Risk with SGLT2

UTI and yest infections

92
New cards

MOA of SGLT2i

SGLT2 normally works to take glucose from the urine in the proximal tubule and reabsorb it back into the kidney, increasing blood glucose.

SGLT2 inhibitors block this reabsorption and increase glucose excretion into the urine

93
New cards

Invokamet

Combination of Canagliflozin and metformin

Works to decrease glucose production and decrease sugar reabsorption

94
New cards

Synjardy

Combination of Empagliflozin and metformin

Decrease glucose production and decrease sugar reabsorption

95
New cards

Pioglitazone (Actos)

Thiazolidinedione

96
New cards

Thiazolidinediones

Peroxisome proliferator activated receptor gamma ligands (PPARy)

Enhance insulin sensitivity in peripheral tissues

Considered to be euglycemic → bring blood to normal range


97
New cards

PPARy

Nuclear receptor (moderates transcription) expressed in liver and adipocytes, as well as other tissues

Regulates fatty acid storage and glucose utilization (metabolism)

When PPARy is activated it stimulate pathways that improve insulin signaling

Makes tissues more responsive to insulin

Mainly work is adipose and skeletal muscle because they are the main victims of insulin resistance

Also decrease liver glucose output by improving the livers insulin resistance and turn off glucagon signaling to decrease glucose outpu

98
New cards

Thiazolidinediones/Glitazone MOA

When activated PPARy forms a heterodimer with RXR

bind to PPRE (response elements)

Changes gene transcription in cell nucleus

Net result is improved insulin sensitivity

99
New cards

AEs of thiazolidinediones

Adipocyte differentiation is modified which can lead to obesity

Leptin level increase leading to a decrease appetite

Some ILs decrease such as IL-6, could decrease inflammation in adipose tissue (Increase adiponectin levels)

Fluid retention

100
New cards

Pioglitazone activity

PPARa and PPARy activity

Metabolized by CYP3A4 and CYP2C8 into active metabolites

Also has TG lowering effects